HRP20130809T1 - Dijagnoza preeklampsije - Google Patents

Dijagnoza preeklampsije

Info

Publication number
HRP20130809T1
HRP20130809T1 HRP20130809AT HRP20130809T HRP20130809T1 HR P20130809 T1 HRP20130809 T1 HR P20130809T1 HR P20130809A T HRP20130809A T HR P20130809AT HR P20130809 T HRP20130809 T HR P20130809T HR P20130809 T1 HRP20130809 T1 HR P20130809T1
Authority
HR
Croatia
Prior art keywords
diagnosis
preeclampsia
relates
disease
haemoglobin
Prior art date
Application number
HRP20130809AT
Other languages
English (en)
Croatian (hr)
Inventor
Stefan Hansson
Bo Åkerström
Original Assignee
A1M Pharma Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by A1M Pharma Ab filed Critical A1M Pharma Ab
Publication of HRP20130809T1 publication Critical patent/HRP20130809T1/hr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/41—Porphyrin- or corrin-ring-containing peptides
    • A61K38/42—Haemoglobins; Myoglobins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
    • C12Y114/99—Miscellaneous (1.14.99)
    • C12Y114/99003—Heme oxygenase (1.14.99.3)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
    • G01N33/721—Haemoglobin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/36—Gynecology or obstetrics
    • G01N2800/368—Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • General Engineering & Computer Science (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
HRP20130809AT 2007-02-12 2008-02-12 Dijagnoza preeklampsije HRP20130809T1 (xx)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0700339 2007-02-12
PCT/EP2008/001051 WO2008098734A1 (en) 2007-02-12 2008-02-12 Diagnosis and treatment of preeclampsia

Publications (1)

Publication Number Publication Date
HRP20130809T1 true HRP20130809T1 (xx) 2013-10-11

Family

ID=39295873

Family Applications (2)

Application Number Title Priority Date Filing Date
HRP20130809AT HRP20130809T1 (xx) 2007-02-12 2008-02-12 Dijagnoza preeklampsije
HRP20161266TT HRP20161266T1 (hr) 2007-02-12 2016-10-03 Dijagnoza i liječenje preeklampsije

Family Applications After (1)

Application Number Title Priority Date Filing Date
HRP20161266TT HRP20161266T1 (hr) 2007-02-12 2016-10-03 Dijagnoza i liječenje preeklampsije

Country Status (18)

Country Link
US (3) US8568999B2 (https=)
EP (3) EP2111555B1 (https=)
JP (2) JP5604111B2 (https=)
KR (2) KR101454013B1 (https=)
AU (1) AU2008214837B2 (https=)
BR (1) BRPI0808340A2 (https=)
CA (1) CA2674204C (https=)
DK (2) DK2111555T3 (https=)
EA (2) EA031877B1 (https=)
ES (2) ES2426069T3 (https=)
HR (2) HRP20130809T1 (https=)
HU (1) HUE031613T2 (https=)
MX (2) MX347788B (https=)
NZ (1) NZ578077A (https=)
PL (2) PL2614832T3 (https=)
PT (2) PT2614832T (https=)
WO (1) WO2008098734A1 (https=)
ZA (1) ZA200905101B (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008098734A1 (en) 2007-02-12 2008-08-21 Stefan Hansson Diagnosis and treatment of preeclampsia
HRP20160760T1 (hr) * 2008-07-18 2016-08-12 A1M Pharma Ab Medicinska uporaba čistača radikala i antioksidacijskog alfa-1-mikroglobulina
WO2011095981A1 (en) * 2010-02-03 2011-08-11 St. John's Research Institute An in-vitro method for characterizing hemoglobin variant
DK2550535T3 (en) 2010-03-24 2015-07-27 Preelumina Diagnostics Ab HBF AND A1M MARKING AT AN EARLY STAGE
JP5914326B2 (ja) * 2010-03-31 2016-05-11 積水メディカル株式会社 イムノクロマトグラフィーを利用した測定方法、イムノクロマトグラフィー用テストストリップ及びイムノクロマトグラフィー用測定試薬キット
EP2766726A1 (en) 2011-10-14 2014-08-20 Aarhus Universitet Diagnostic and prognostic use of prombp-complexes
JP2015533790A (ja) * 2012-09-05 2015-11-26 エー１エム ファーマ エービーＡ１Ｍ Ｐｈａｒｍａ ＡＢ ミトコンドリア関連疾患の治療に使用するためのα−１−ミクログロブリン
US10928402B2 (en) 2012-12-28 2021-02-23 Nx Prenatal Inc. Treatment of spontaneous preterm birth
US20140186332A1 (en) * 2012-12-28 2014-07-03 NX Pharmagen Biomarkers of preterm birth
TW201702383A (zh) 2015-03-16 2017-01-16 Ａ１Ｍ藥品公司 用於子癇前症之生物標記
KR101732933B1 (ko) 2015-07-29 2017-05-08 영남대학교 산학협력단 신생아의 성장 또는 심혈관계 질환 예후 진단 방법
CN109072479A (zh) 2015-12-04 2018-12-21 Nx产前公司 使用循环微粒对自发性早产风险进行分层
CA3089655C (en) * 2018-03-19 2026-01-20 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
US12259355B2 (en) 2018-03-19 2025-03-25 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
US12253490B2 (en) 2018-03-19 2025-03-18 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
US11418353B2 (en) * 2019-08-26 2022-08-16 Micron Technology, Inc. Security descriptor generation
CN111626280B (zh) * 2020-04-13 2021-09-07 北京邮电大学 一种无定位点答题卡识别方法和装置
WO2024053586A1 (ja) * 2022-09-05 2024-03-14 栄研化学株式会社 遊離ヘモグロビン測定試薬、遊離ヘモグロビン測定方法および抗ヘモグロビン抗体
KR20250145250A (ko) * 2024-03-28 2025-10-13 계명대학교 산학협력단 Ccl20 및 csf3 단백질 또는 상기 단백질을 코딩하는 유전자를 유효성분으로 포함하는 태아성장제한 진단용 바이오마커 조성물

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1337778A1 (ru) 1984-06-25 1987-09-15 Новосибирский государственный медицинский институт Способ диагностики т жести позднего токсикоза беременных
US5079171A (en) 1988-09-15 1992-01-07 Adeza Biomedical Corporation Determining pregnancy induced hypertension and eclampsia by immunoassay of cellular fibronectin
US5238819A (en) 1988-12-14 1993-08-24 The Regents Of The University Of California Diagnostic assay for the detection of preeclampsia
US5939272A (en) 1989-01-10 1999-08-17 Biosite Diagnostics Incorporated Non-competitive threshold ligand-receptor assays
US5108898A (en) 1989-01-18 1992-04-28 Peters John H Use of fibronectin having a variable included type III repeat sequence as a marker for toxemia in pregnancy
US5612034A (en) * 1990-10-03 1997-03-18 Redcell, Inc. Super-globuling for in vivo extended lifetimes
US5166133A (en) 1991-04-17 1992-11-24 Cetus Corporation Method for inhibing adhesion of white blood cells to endothelial cells
US6103691A (en) 1994-03-23 2000-08-15 Tschesche; Harald Utilisation of angiogenin and/or α1 -microglobulin and/or complement factor D in order to inhibit the secretion of proteins
US5849474A (en) * 1995-12-06 1998-12-15 Olson; Camilla M. Diagnosis of preeclampsia in mammals
US5910482A (en) * 1996-03-19 1999-06-08 Board Of Regents, The University Of Texas System Treatment or prevention of preeclampsia, eclampsia with calcitonin gene related peptide, CGRP analog, progestational agent, nitric oxide source, and cyclooxygenase inhibitor
US6169816B1 (en) * 1997-05-14 2001-01-02 Applied Imaging, Inc. Identification of objects of interest using multiple illumination schemes and finding overlap of features in corresponding multiple images
JP2001348342A (ja) 2001-04-12 2001-12-18 Nippon Zoki Pharmaceut Co Ltd 免疫調整・抗炎症剤
ATE458199T1 (de) 2001-05-04 2010-03-15 Biosite Inc Diagnostische marker der akuten koronaren syndrome und ihre verwendungen
DE60219642T2 (de) 2001-09-04 2008-01-17 Iq Corp. B.V. Bestimung und quantifizierung von erythrocytenpopulation in proben
US20050014275A1 (en) * 2002-03-29 2005-01-20 Fumihisa Kitawaki Blood processing method, blood processing device, method of measuring hemoglobins and device for measuring hemoglobins
DE10237423A1 (de) 2002-08-16 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von LCK-Inhibitoren für die Behandlung von immunologischen Erkrankungen
CA2525236C (en) * 2003-06-20 2015-03-24 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
AR045074A1 (es) 2003-07-23 2005-10-12 Applied Research Systems Uso de cd164 soluble en desordenes inflamatorios y autoinmunes
CA2547124A1 (en) * 2003-11-26 2005-06-09 Sanofi-Aventis Deutschland Gmbh Tubular proteinuria as an indicator for elevated cardiovascular risk
WO2005093413A2 (en) 2004-03-22 2005-10-06 Yale University Diagnosis and treatment of preeclampsia
US20070292421A1 (en) * 2005-07-28 2007-12-20 Feinberg Bruce B Method for treating preeclampsia
GB0600916D0 (en) 2006-01-17 2006-02-22 Perkinelmer Instr Las Inc detecting and predicting pre-eclampsia
JP2009524031A (ja) * 2006-01-18 2009-06-25 ヴィック、イミュノロジッシェ ダイアグノステック ウー．ベラートゥング カーゲー シリコンに接着するポリペプチドおよび細胞を分析するための試験系
WO2008098734A1 (en) 2007-02-12 2008-08-21 Stefan Hansson Diagnosis and treatment of preeclampsia
WO2009108073A1 (en) 2008-02-28 2009-09-03 Auckland Uniservices Limited Biomarkers for prediction of preeclampsia and/or cardiovascular disease
HRP20160760T1 (hr) 2008-07-18 2016-08-12 A1M Pharma Ab Medicinska uporaba čistača radikala i antioksidacijskog alfa-1-mikroglobulina
DK2550535T3 (en) 2010-03-24 2015-07-27 Preelumina Diagnostics Ab HBF AND A1M MARKING AT AN EARLY STAGE

Also Published As

Publication number Publication date
EP2614832A1 (en) 2013-07-17
US20180284087A1 (en) 2018-10-04
EP2111555B1 (en) 2013-05-29
US20140065170A1 (en) 2014-03-06
JP5792772B2 (ja) 2015-10-14
BRPI0808340A2 (pt) 2017-05-30
ES2426069T3 (es) 2013-10-21
PL2111555T3 (pl) 2013-10-31
ES2599003T3 (es) 2017-01-31
JP5604111B2 (ja) 2014-10-08
JP2010518386A (ja) 2010-05-27
AU2008214837A1 (en) 2008-08-21
US8568999B2 (en) 2013-10-29
MX347788B (es) 2017-05-12
EP2614832B1 (en) 2016-07-13
DK2111555T3 (da) 2013-09-02
EA201500335A1 (ru) 2016-08-31
EP2111555A1 (en) 2009-10-28
EA200970758A1 (ru) 2010-02-26
DK2614832T3 (da) 2016-10-31
US10359406B2 (en) 2019-07-23
PT2111555E (pt) 2013-09-04
KR20140095572A (ko) 2014-08-01
MX2009008408A (es) 2009-11-02
KR101608501B1 (ko) 2016-04-04
EA031877B1 (ru) 2019-03-29
JP2014012670A (ja) 2014-01-23
HUE031613T2 (en) 2017-09-28
NZ578077A (en) 2012-04-27
PT2614832T (pt) 2016-10-18
CA2674204C (en) 2017-07-11
ZA200905101B (en) 2012-01-25
WO2008098734A1 (en) 2008-08-21
HRP20161266T1 (hr) 2016-12-16
EP2613150A1 (en) 2013-07-10
AU2008214837B2 (en) 2013-01-10
KR101454013B1 (ko) 2014-11-12
CA2674204A1 (en) 2008-08-21
EA022609B1 (ru) 2016-02-29
PL2614832T3 (pl) 2017-01-31
US20100105070A1 (en) 2010-04-29
KR20100015315A (ko) 2010-02-12

Similar Documents

Publication Publication Date Title
HRP20130809T1 (xx) Dijagnoza preeklampsije
WO2009100131A3 (en) Process to diagnose or treat brain injury
EA201290716A1 (ru) Способы и композиции для неинвазивной пренатальной диагностики анеуплоидии плода
WO2010053587A3 (en) Methods of monitoring conditions by sequence analysis
BRPI0507442B8 (pt) método in vitro de diagnóstico de um indivíduo humano gestante como apresentando ou com uma propensão a desenvolver pré-eclâmpsia ou eclâmpsia
WO2010056337A3 (en) Methods and systems of using exosomes for determining phenotypes
WO2008005814A3 (en) Method and apparatus for diagnosing pre-eclampsia
WO2010091049A3 (en) Diagnosis and treatment of cancer
EP2557425A3 (en) Methods and products for diagnosing autoimmune diseases and gastric cancer linked with atrophic gastritis
ATE550658T1 (de) Verfahren für den nachweis oder die diagnose neurodegenerativer erkrankungen oder leiden
ATE527544T1 (de) Vorhersage von letalität und detektion von schweren erkrankungen
DE602006011896D1 (de) Diagnoseverfahren für erkrankungen im zusammenhang mit hirnschäden
BR112013010015A2 (pt) aparelho e método para detecção não invasiva de doenças que afetam as propriedades estruturais em tecidos biológicos
BR112013033488A2 (pt) marcadores biológicos de micro-rna indicativo da doença de alzheimer
SI1994410T1 (sl) Metode in kompleti za zgodnje odkrivanje raka ali predispozicije zanj
WO2010090834A3 (en) Netrin-1 as a biomarker of injury and disease
WO2010138610A3 (en) Novel desmin phosphorylation sites useful in diagnosis and intervention of cardiac disease
WO2007067719A3 (en) Diagnosing human diseases by detecting dna methylation changes
WO2007109293A3 (en) Early diagnosis of congenital abnormalities in the offspring of diabetic mothers
DE602005023009D1 (de) Verfahren in echtzeit zur erkennung von akuten entzündungszuständen
PL1884775T3 (pl) Sposób rozpoznawania chorób związanych z przeciwciałem przeciwko receptorowi AT 1
WO2008057966A3 (en) A panel of biomarkers for peripheral arterial disease
WO2009069007A3 (en) Composition and method for prediction of complicated disease course in crohn's disease
RU2011116505A (ru) Способ диагностики различных форм острого пиелонефрита
CY1112415T1 (el) Η πρωτεϊνη serum amyloid p-component (sap, samp) ως προγνωστικος και διαγνωστικος δεικτης για τον προγεννητικο ελεγχο της τρισωμιας 21 (συνδρομο down)